Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Inclusion Criteria

• •1. Male or female patients aged ≥40 years based on the date of the written informed consent form
• •2. Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines
• •3. In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation
• •4. Meeting all of the following criteria during the screening period:
• •1. FVC ≥40% predicted normal
• •2. DLCO corrected for Hgb ≥25% and \<80% predicted normal
• •3. Forced Expiratory Volume in the first second/FVC (FEV1/FVC) ratio \>0.7 based on pre-bronchodilator value